The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).
Eleonora Teplinsky
No relevant relationships to disclose
Amanda Valeta
No relevant relationships to disclose
Rezina Arju
No relevant relationships to disclose
Shah Giashuddin
No relevant relationships to disclose
Yasmeen Sarfraz
No relevant relationships to disclose
Melissa Alexander
No relevant relationships to disclose
Farbod Darvishian
No relevant relationships to disclose
Deborah Silvera
No relevant relationships to disclose
Paul H. Levine
No relevant relationships to disclose
Salman Hashmi
No relevant relationships to disclose
Ladan Paul
No relevant relationships to disclose
Heather J. Hoffman
No relevant relationships to disclose
Baljit Singh
No relevant relationships to disclose
Judith D. Goldberg
No relevant relationships to disclose
Tsivia Hochman
No relevant relationships to disclose
Silvia Formenti
No relevant relationships to disclose
Robert Schneider
No relevant relationships to disclose
Komal L. Jhaveri
No relevant relationships to disclose